Fennec (NASDAQ: FENC) Chief Strategy Officer exercises options, holds 145,300 shares

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi exercised stock options to acquire 4,700 common shares at an exercise price of $4.23 per share. Following the transaction, she holds 145,300 common shares directly, indicating an exercise-and-hold transaction with no reported share sales.

Insider Trade Summary

4,700 shares exercised/converted

Mixed 2 txns

Insider Cioffi Christiana Marie

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Exercise	Stock Options	4,700	$4.23	$20K
Exercise	Common shares	4,700	$4.23	$20K

Holdings After Transaction: Stock Options — 145,300 shares (Direct); Common shares — 4,700 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cioffi Christiana Marie

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	03/26/2026		M		4,700	A	$4.23	4,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options(1)	$4.23	03/26/2026		M			4,700	11/13/2025	11/13/2034	Common Shares	4,700	$4.23	145,300	D

Explanation of Responses:

1. Shares acquired through the exercise of an option contract with strike price of $4.23 and an expiration date of November 13, 2034.

	/s/ Christiana Cioffi	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did FENC Chief Strategy Officer Christiana Cioffi report?

Christiana Cioffi reported exercising stock options to acquire 4,700 Fennec Pharmaceuticals common shares at an exercise price of $4.23 per share. The Form 4 classifies this as an option exercise, not an open-market purchase or sale, and shows it as a routine compensation-related transaction.

How many FENC shares does Christiana Cioffi hold after this Form 4 transaction?

After the reported option exercise, Christiana Cioffi directly holds 145,300 Fennec Pharmaceuticals common shares. This figure reflects her total direct ownership following the acquisition of 4,700 shares through the exercised stock options disclosed in the Form 4 insider filing.

Was the FENC Form 4 transaction a buy or a sale of shares?

The Form 4 shows an option exercise, classified as an acquisition of shares rather than an open-market buy or sale. Cioffi exercised stock options to receive 4,700 common shares at $4.23 and did not report any concurrent sales or tax-withholding dispositions.

What were the key terms of the FENC stock options exercised by Christiana Cioffi?

The stock options carried a strike price of $4.23 per share and an expiration date of November 13, 2034. Cioffi exercised options covering 4,700 underlying common shares, converting these derivative securities into directly held Fennec Pharmaceuticals common shares.

Does the FENC Form 4 show any remaining stock options for Christiana Cioffi?

The derivative summary in the Form 4 is empty, indicating no remaining derivative positions are reported in this specific filing. It focuses on the completed exercise of options for 4,700 shares, with no additional unexercised options listed in the visible data.

How significant is Christiana Cioffi’s 4,700-share option exercise in the context of her FENC holdings?

The 4,700-share option exercise is relatively small compared with Cioffi’s total post-transaction holding of 145,300 common shares. This suggests a routine exercise-and-hold event, typical of equity compensation programs, rather than a large change in insider ownership.